Cytokinetics Announces Proposed Public Offering of Common Stock
Rhea-AI Summary
Cytokinetics (Nasdaq: CYTK) announced a proposed underwritten public offering of approximately $650 million of common stock, with an expected 30-day underwriter option to purchase up to an additional 15% of shares. All offered shares will be sold by Cytokinetics.
The offering is subject to market and other conditions; a preliminary prospectus supplement will be filed with the SEC and will be publicly available.
Positive
- Proposed capital raise of approximately $650 million
- Underwriter option allows sale of up to an additional 15% of shares
- Shelf registration for the offering is already effective with the SEC
Negative
- Potential dilution because all offered shares are being sold by the company
- No assurance the offering will be completed or finalized on the proposed size or terms
News Market Reaction – CYTK
In the May 6 session, CYTK declined 2.92%, reflecting a moderate negative market reaction. Argus tracked a peak move of +32.7% during that session. Argus tracked a trough of -16.9% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Sep 16 | Convertible notes offering | Negative | -4.4% | Upsized $650.0M 2031 convertible notes to refinance 2027 notes and fund growth. |
| May 28 | Equity offering closing | Negative | -0.7% | Closing of $500M common stock offering under prior shelf registration. |
| May 22 | Equity offering pricing | Negative | -17.3% | Pricing of 9.8M shares at $51.00 for $500M gross proceeds. |
| May 22 | Equity offering proposal | Negative | -17.3% | Announcement of proposed $500M common stock offering with 15% underwriter option. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Offering-related announcements have historically been followed by negative moves, with an average move of -9.94% across the past four such events.
Historically, Cytokinetics’ capital-raising announcements have coincided with share price pressure. In May 2024, a proposed and then priced common stock offering around $500 million saw -17.31% moves on both the proposal and pricing dates, and -0.73% on closing. A $650.0 million convertible notes deal in September 2025 coincided with a -4.42% move. Today’s proposed equity raise follows this pattern of market sensitivity to financing news.
Key Terms
underwritten public offering financial
shelf registration statement regulatory
base prospectus regulatory
preliminary prospectus supplement regulatory
Securities and Exchange Commission (SEC) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced plans to offer, subject to market and other conditions, approximately
Morgan Stanley, Goldman Sachs & Co. LLC, J.P. Morgan and Jefferies are acting as joint book-running managers for the offering.
The securities described above are being offered by Cytokinetics pursuant to a shelf registration statement (including a base prospectus) filed on February 27, 2025 with the Securities and Exchange Commission (SEC), which has become automatically effective. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free on the SEC’s website at http://www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering, when available, may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by telephone at 866-718-1649 or by email at prospectus@morganstanley.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at (866) 471-2526 or by email at Prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Cytokinetics
Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the U.S., Europe and China for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the Act). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ expectations regarding the completion, timing and size of the proposed offering. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, risks and uncertainties related to whether or not Cytokinetics will be able to raise capital through the sale of its securities, the final terms of the proposed offering, market and other conditions, and the satisfaction of customary closing conditions related to the proposed public offering. There can be no assurance that Cytokinetics will be able to complete the proposed public offering on the anticipated terms, or at all. You should not place undue reliance on these forward-looking statements. Additional risks and uncertainties relating to the proposed public offering, Cytokinetics and its business can be found under the heading “Risk Factors” in Cytokinetics’ Annual Report on Form 10-K for the year ended December 31, 2025, which was filed on February 26, 2026, Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, which was filed on May 5, 2026, and other filings with the SEC, and in the preliminary prospectus supplement related to the proposed public offering to be filed with the SEC on or about the date hereof. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
